Head to Head Survey: PDL Biopharma (PDLI) and Curis (CRIS)

PDL Biopharma (NASDAQ: PDLI) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Profitability

This table compares PDL Biopharma and Curis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
PDL Biopharma 34.60% 12.03% 7.81%
Curis -538.66% -250.55% -72.61%



Institutional & Insider Ownership

91.4% of PDL Biopharma shares are held by institutional investors. Comparatively, 47.7% of Curis shares are held by institutional investors. 2.2% of PDL Biopharma shares are held by insiders. Comparatively, 4.1% of Curis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares PDL Biopharma and Curis’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PDL Biopharma $320.06 million 1.44 $110.74 million $0.63 4.76
Curis $9.90 million 10.14 -$53.31 million ($0.36) -1.68

PDL Biopharma has higher revenue and earnings than Curis. Curis is trading at a lower price-to-earnings ratio than PDL Biopharma, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

PDL Biopharma has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500. Comparatively, Curis has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for PDL Biopharma and Curis, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PDL Biopharma 0 1 1 0 2.50
Curis 0 0 2 0 3.00

PDL Biopharma currently has a consensus price target of $3.50, suggesting a potential upside of 16.67%. Curis has a consensus price target of $7.00, suggesting a potential upside of 1,054.92%. Given Curis’ stronger consensus rating and higher probable upside, analysts clearly believe Curis is more favorable than PDL Biopharma.

Summary

PDL Biopharma beats Curis on 8 of the 14 factors compared between the two stocks.

PDL Biopharma Company Profile

PDL BioPharma, Inc. acquires and manages companies, products, royalty agreements, and debt facilities in the biotech, pharmaceutical, and medical device industries in the United States, Europe, and internationally. The company operates through two segments, Income Generating Assets and Product Sales. The Income Generating Assets segment consists of royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, and Tysabri; and notes and other long-term receivables, royalty rights, hybrid notes/royalties receivable, and equity investments in healthcare companies. The Product Sales segment, through its equity and loan investments, manufactures, markets, and sells prescription pharmaceutical products under the Tekturna and Tekturna HCT names in the United States; and Rasilez and Rasilez HCT names internationally for the treatment of hypertension. This segment sells its products primarily to wholesalers. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

Curis Company Profile

Curis, Inc., a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. The company has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.

Receive News & Ratings for PDL Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDL Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply